<DOC>
	<DOCNO>NCT03010787</DOCNO>
	<brief_summary>A multi-part study investigate safety , tolerability local systemic pharmacokinetics V565</brief_summary>
	<brief_title>A First Time Human Study Healthy Volunteers Patients</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Parts 1 2 1 . Adult male subject age 18 45 year inclusive . 2 . Body mass index ( BMI ) 18.0 32.0 kg/m2 inclusive . 3 . Body weight 50.0 100.0 kg inclusive . 4 . Subjects healthy determine pre study medical history , physical examination 12lead ECG , clinical laboratory test Part 3 1 . Adult male female subject age 18 65 year . 2 . Ileostomy minimum 18 month non malignant disease indication . 3 . A BMI 18.0 32.0 kg/m2 inclusive . 4 . Body weight 50.0 100.0 kg inclusive . 5 . Subjects healthy determine pre study medical history , physical examination 12lead ECG , clinical laboratory test Part 4 1 . Adult male female subject age 18 65 year . 2 . A confirmed diagnosis Crohn 's disease minimum 6 month . 3 . A BMI 15.0 32.0 kg/m2 inclusive . 4 . Subjects significant comorbidity ( associate Crohn 's disease ) . 5 . Subjects whose medical history , physical examination , clinical laboratory test result 12lead ECG clinically relevant abnormality ( associate Crohn 's disease ) . Parts 1 2 1 . A clinically significant abnormal medical history clinically significant abnormal physical examination , include history febrile illness within 1 week prior first dose . 2 . A history severe allergy , nonallergic drug reaction , multiple drug allergy . 3 . A known hypersensitivity TNF inhibitor inactive ingredient study treatment . 4 . A history significant gastrointestinal ( GI ) disease , include GI motility disorder , GI malignancy polyposis coli . 5 . Previous surgery GI tract exception appendectomy . 6 . A history malignancy . 7 . Any condition investigator 's opinion interfere trial interpretation result . Part 3 1 . A history Crohn 's disease . 2 . A clinically significant abnormal medical history ( condition lead ileostomy ) clinically significant abnormal physical examination , include history febrile illness within 1 week prior first dose . 3 . A history severe allergy , nonallergic drug reaction , multiple drug allergy . 4 . A known hypersensitivity contraindication TNF inhibitor inactive ingredient study treatment . 5 . A known history heart disease . 6 . Any clinical evidence active inflammatory bowel disease . 7 . Any condition investigator 's opinion interfere trial interpretation result . Part 4 1 . Subjects severe Crohn 's disease : requiring surgery ; current abscess ; non inflammatory stricture ; history obstruction . 2 . Having ever receive antiTNFÎ± therapy biologics . 3 . Required increase dose either steroid immunosuppressant therapy within past 6 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>